Ofloxacin Otic
PreclinicalSmall molecule
Ofloxacin Otic is one of 25 small molecule programs targeting Acute otitis media. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Acute Otitis Media
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Singulair
OOrganon and Co
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Omnicef
AbbViePhase 3
Ketek
SanofiPhase 3
Pneumococcal Vaccine
GSKPhase 3
GSK 257049
GSKPhase 3
Engerix-B
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute otitis media2 trials
Surgery1 trial
Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present
Recruiting·—·Phase 4·NCT03655665·125 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ofloxacin Otic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAlcon Research